GlassScriptPhysician profile
Stephen Piccione
NPI 1811918295
$2,049.79
in general payments reported to CMS, 2019-2025
25 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $199 · 2021: $441 · 2022: $282 · 2023: $185 · 2024: $313 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $231.87 | 2019-2025 | Otezla, Repatha, Prolia |
| Pfizer INC. | $222.88 | 2019-2025 | |
| Corcept Therapeutics | $191.05 | 2021-2025 | Korlym |
| Lilly USA, LLC | $182.10 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $157.55 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $130.91 | 2019-2025 | Airsupra |
| Exact Sciences Corporation | $114.67 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $109.48 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Esperion Therapeutics, INC. | $108.23 | 2020-2024 | Nexletol |
| Mylan Specialty L.P. | $102.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $80.79 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $77.57 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $65.81 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Abbott Laboratories | $41.75 | 2020-2025 | Freestyle Libre |
| Abbvie INC. | $39.43 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $37.23 | 2019-2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $27.52 | 2020-2023 | |
| Xeris Pharmaceuticals, INC. | $22.51 | 2023 | Gvoke Hypopen |
| Allergan, INC. | $17.64 | 2020 | |
| Sunovion Pharmaceuticals INC. | $17.30 | 2021 | |
| Eisai INC. | $16.33 | 2021 | |
| Boston Scientific Corporation | $15.29 | 2020 | |
| Painteq LLC | $13.83 | 2021 | |
| Glaxosmithkline, LLC. | $13.37 | 2024 | Trelegy Ellipta |
| Ethicon US, LLC | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Piccione listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.